Rivaroxaban given to medically ill patients after discharge from hospital does not reduce the risk of venous thromboembolism (VTE), according to data from the MARINER trial presented at the 2018 ESC Congress. A total of 12,024 patients who were at increased risk of VTE were randomly assigned at discharge from hospital to 10 mg of rivaroxaban once daily or placebo for 45 days. No significant difference in the rate of the primary efficacy end point (a composite of symptomatic VTE or death from VTE) was observed between rivaroxaban and placebo (0.83% versus 1.10%; HR 0.76, 95% CI 0.52–1.09). The rate of the principal safety outcome (major bleeding) was similar in the two groups (0.28% versus 0.15%; HR 1.88, 95% CI 0.84–4.23).
References
Original article
Spyropoulos, A. C. et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1805090 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, G.B. Rivaroxaban for prevention of VTE. Nat Rev Cardiol 15, 653 (2018). https://doi.org/10.1038/s41569-018-0083-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-018-0083-z
